Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Synlogic Inc    SYBX

SYNLOGIC INC

(SYBX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Synlogic : Ginkgo expand synthetic biology research pact

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2019 | 06:36am EDT

Synlogic has tapped Ginkgo Bioworks for a cell programming platform to support development of its pipeline of engineered microbes.

Massachusetts-based synthetic biology startup Synlogic began working with Ginkgo in 2017 to gain access to high-throughput organism screening and design capabilities. The goal was to accelerate the development of what Synlogic calls Synthetic Biotic medicines, microbes genetically engineered to counter the biology that drives diseases including hyperammonemia and forms of cancer.

Now, both parties have stepped up their commitment to the relationship. Synlogic is putting up $30 million to source synthetic biology services from Ginkgo over the next five years.

This collaboration significantly enhances Synlogics Synthetic Biotic strain optimization capabilities. It enables us to advance high-quality candidate strains into development more efficiently and provides technology and resources that will fuel pipeline expansion, Synlogic CEO Aoife Brennan said in a statement.

Ginkgo is committing cash, too, handing over $80 million to buy a stake in Synlogic at a 44% premium to its closing price prior to news of the deal. Synlogics share price leapt 20% in premarket trading.

The investment furthers Ginkgos move into biopharma. Ginkgo started out engineering microbes to produce flavors and fragrances. In 2015, Ginkgo floated the prospect of its $45 million series B round supporting a push into biopharma, but the expansion really took off last year when it opened a facility focused on the engineering of mammalian cell genomes for drug research and production.

Synlogic will use Ginkgos technology in a slightly different way. Its focus is on engineering microbes to directly treat disease, for example by consuming ammonia that builds up in patients whose ability to convert the toxin into urea is impaired. That is the idea behind SYNB1020, one of Synlogic's clinical-phase candidates.

Working with Ginkgo, Synlogic thinks it can cut the time it takes to turn early preclinical leads into optimized drug candidates that are ready to join SYNB1020 in the clinic.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNLOGIC INC
06/13SYNLOGIC : Ginkgo expand microbial discovery pact, throwing $80M investment into..
AQ
06/13SYNLOGIC : Ginkgo expand synthetic biology research pact
AQ
06/12SYNLOGIC, INC. : Entry into a Material Definitive Agreement, Unregistered Sale o..
AQ
06/12SYNLOGIC : and Ginkgo Bioworks Establish Transformational Platform Collaboration..
BU
06/05SYNLOGIC, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/22Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors
DJ
05/22SYNLOGIC : Announces Clinical Collaboration to Evaluate SYNB1891 in Combination ..
BU
05/09SYNLOGIC : Reports First Quarter 2019 Financial Results and Provides Business Up..
BU
05/02SYNLOGIC : Announces First Quarter 2019 Conference Call and Webcast
BU
04/30SYNLOGIC : Presents Data Describing a Solid Oral Formulation Process for Synthet..
BU
More news
Financials ($)
Sales 2019 1,89 M
EBIT 2019 -61,3 M
Net income 2019 -59,1 M
Finance 2019 112 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 60,4x
EV / Sales 2020 96,3x
Capitalization 226 M
Chart SYNLOGIC INC
Duration : Period :
Synlogic Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNLOGIC INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 19,0 $
Spread / Average Target 113%
EPS Revisions
Managers
NameTitle
Aoife M. Brennan President, Chief Executive Officer & Director
Peter Barrett Chairman
Todd Shegog Chief Financial Officer
Paul S. Miller Chief Scientific Officer
Michael F. Powell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SYNLOGIC INC26.96%226
CSL LIMITED15.78%67 618
BIOGEN-20.11%46 591
ALEXION PHARMACEUTICALS28.54%28 063
SAMSUNG BIOLOGICS CO LTD--.--%17 955
GRIFOLS8.73%17 311